Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.

Identifieur interne : 002146 ( PubMed/Curation ); précédent : 002145; suivant : 002147

Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.

Auteurs : R. Noordin [Malaisie] ; J. Muhi ; Z. Md Idris ; N. Arifin ; A. Kiyu

Source :

RBID : pubmed:22543621

Descripteurs français

English descriptors

Abstract

The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.

PubMed: 22543621

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:22543621

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</title>
<author>
<name sortKey="Noordin, R" sort="Noordin, R" uniqKey="Noordin R" first="R" last="Noordin">R. Noordin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Muhi, J" sort="Muhi, J" uniqKey="Muhi J" first="J" last="Muhi">J. Muhi</name>
</author>
<author>
<name sortKey="Md Idris, Z" sort="Md Idris, Z" uniqKey="Md Idris Z" first="Z" last="Md Idris">Z. Md Idris</name>
</author>
<author>
<name sortKey="Arifin, N" sort="Arifin, N" uniqKey="Arifin N" first="N" last="Arifin">N. Arifin</name>
</author>
<author>
<name sortKey="Kiyu, A" sort="Kiyu, A" uniqKey="Kiyu A" first="A" last="Kiyu">A. Kiyu</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22543621</idno>
<idno type="pmid">22543621</idno>
<idno type="wicri:Area/PubMed/Corpus">002146</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002146</idno>
<idno type="wicri:Area/PubMed/Curation">002146</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002146</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</title>
<author>
<name sortKey="Noordin, R" sort="Noordin, R" uniqKey="Noordin R" first="R" last="Noordin">R. Noordin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</nlm:affiliation>
<country xml:lang="fr">Malaisie</country>
<wicri:regionArea>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Muhi, J" sort="Muhi, J" uniqKey="Muhi J" first="J" last="Muhi">J. Muhi</name>
</author>
<author>
<name sortKey="Md Idris, Z" sort="Md Idris, Z" uniqKey="Md Idris Z" first="Z" last="Md Idris">Z. Md Idris</name>
</author>
<author>
<name sortKey="Arifin, N" sort="Arifin, N" uniqKey="Arifin N" first="N" last="Arifin">N. Arifin</name>
</author>
<author>
<name sortKey="Kiyu, A" sort="Kiyu, A" uniqKey="Kiyu A" first="A" last="Kiyu">A. Kiyu</name>
</author>
</analytic>
<series>
<title level="j">Tropical biomedicine</title>
<idno type="ISSN">0127-5720</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antibodies, Helminth (blood)</term>
<term>Antigens, Helminth</term>
<term>Brugia (immunology)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Drug Therapy (methods)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (epidemiology)</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Filaricides (administration & dosage)</term>
<term>Humans</term>
<term>Immunoglobulin G (blood)</term>
<term>Malaysia (epidemiology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recombinant Proteins</term>
<term>Seroepidemiologic Studies</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (sang)</term>
<term>Antigènes d'helminthe</term>
<term>Brugia (immunologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs temps</term>
<term>Filaricides (administration et posologie)</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (épidémiologie)</term>
<term>Humains</term>
<term>Immunoglobuline G (sang)</term>
<term>Jeune adulte</term>
<term>Malaisie (épidémiologie)</term>
<term>Mâle</term>
<term>Protéines recombinantes</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Traitement médicamenteux ()</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Antibodies, Helminth</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Malaysia</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Brugia</term>
<term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Brugia</term>
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Drug Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Anticorps antihelminthe</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Filariose lymphatique</term>
<term>Malaisie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antigens, Helminth</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Recombinant Proteins</term>
<term>Seroepidemiologic Studies</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Antigènes d'helminthe</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs temps</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Protéines recombinantes</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Traitement médicamenteux</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Malaisie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22543621</PMID>
<DateCreated>
<Year>2012</Year>
<Month>04</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>2012</Year>
<Month>08</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0127-5720</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2012</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Tropical biomedicine</Title>
<ISOAbbreviation>Trop Biomed</ISOAbbreviation>
</Journal>
<ArticleTitle>Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.</ArticleTitle>
<Pagination>
<MedlinePgn>191-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The detection rates of brugian filariasis in three regions of Sarawak namely Central, North and South after three courses of mass drug administration (MDA) from year 2004 to 2006 was investigated. A recombinant BmR1 antigen-based IgG4 detection test, named Brugia Rapid and night blood smear for microfilaria (mf) detection were used. All three regions recorded a sharp fall in mf positive rates after a year post-MDA. Meanwhile Brugia Rapid positive rates declined more gradually to 3.8% and 5.6% of the pre-MDA levels in the Central and North regions, respectively. This study showed that in filariasis endemic areas in Sarawak, anti-filarial IgG4 antibodies to BmR1, as detected by the Brugia Rapid test, were positive for one to two years after mf disappearance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Noordin</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia. rahmah8485@gmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Muhi</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Md Idris</LastName>
<ForeName>Z</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Arifin</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kiyu</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Malaysia</Country>
<MedlineTA>Trop Biomed</MedlineTA>
<NlmUniqueID>8507086</NlmUniqueID>
<ISSNLinking>0127-5720</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002009" MajorTopicYN="N">Brugia</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2012</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2012</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>8</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22543621</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002146 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002146 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:22543621
   |texte=   Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:22543621" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024